Considerations When Treating Patients with Good-risk Germ Cell Tumors

Aditya Bagrodia, Costantine Albany, K. Clinton Cary

Research output: Contribution to journalArticle

Abstract

Three cycles of bleomycin, etoposide, and cisplatin or four cycles of etoposide and cisplatin are options for patients with good-risk germ cell tumors. Despite no significant differences in clinical outcomes in a randomized trial, studies suggest variable impact on postchemotherapy retroperitoneal lymph node dissection histology, which may help inform treatment decisions.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Germ Cell and Embryonal Neoplasms
Etoposide
Cisplatin
Bleomycin
Lymph Node Excision
Histology
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Considerations When Treating Patients with Good-risk Germ Cell Tumors. / Bagrodia, Aditya; Albany, Costantine; Cary, K. Clinton.

In: European Urology Focus, 01.01.2019.

Research output: Contribution to journalArticle

@article{84ba18d05453497390120fbd4c83ba1c,
title = "Considerations When Treating Patients with Good-risk Germ Cell Tumors",
abstract = "Three cycles of bleomycin, etoposide, and cisplatin or four cycles of etoposide and cisplatin are options for patients with good-risk germ cell tumors. Despite no significant differences in clinical outcomes in a randomized trial, studies suggest variable impact on postchemotherapy retroperitoneal lymph node dissection histology, which may help inform treatment decisions.",
author = "Aditya Bagrodia and Costantine Albany and Cary, {K. Clinton}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.euf.2019.01.002",
language = "English (US)",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Considerations When Treating Patients with Good-risk Germ Cell Tumors

AU - Bagrodia, Aditya

AU - Albany, Costantine

AU - Cary, K. Clinton

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Three cycles of bleomycin, etoposide, and cisplatin or four cycles of etoposide and cisplatin are options for patients with good-risk germ cell tumors. Despite no significant differences in clinical outcomes in a randomized trial, studies suggest variable impact on postchemotherapy retroperitoneal lymph node dissection histology, which may help inform treatment decisions.

AB - Three cycles of bleomycin, etoposide, and cisplatin or four cycles of etoposide and cisplatin are options for patients with good-risk germ cell tumors. Despite no significant differences in clinical outcomes in a randomized trial, studies suggest variable impact on postchemotherapy retroperitoneal lymph node dissection histology, which may help inform treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=85059700928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059700928&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.01.002

DO - 10.1016/j.euf.2019.01.002

M3 - Article

AN - SCOPUS:85059700928

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -